## ICUI: ICU Medical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.2% below STRENGTH zone (4.0-10.0%); PEG 1.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-8.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($131.87)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. ICU Medical (ICUI): Reassessing Valuation After a 22% One-Month Share Price Rebound**
- Source: Sahm | 20251204T041120 | Somewhat-Bullish | Relevance: 100%
- ICU Medical (ICUI) has seen its stock rebound by 22% over the past month, prompting a reassessment of its valuation. While one narrative suggests the company is 18.9% undervalued with a fair value of $180.83 due to improving margins and integration synergies, another perspective highlights that its 1.6x price-to-sales multiple is above its 1.0x fair ratio, despite being below industry averages. Investors are left to weigh whether the recent rally fully accounts for the recovery or if further upside exists.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-07 | Keybanc | $175 | $173 | +1% |
| 2025-11-07 | Piper Sandler | $172 | $153 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-07 | Keybanc | main | Overweight |
| 2025-11-07 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.3% (-1.2%)
- Vanguard Group Inc: 10.6% (-1.3%)
- Janus Henderson Grou: 10.0% (+0.1%)
- Fuller & Thaler Asse: 5.6% (-0.3%)
- JPMORGAN CHASE & CO: 5.5% (+78.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-8.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.70 elevated, pricing in significant growth expectations. Forward P/E 17.8x stretched relative to 6% growth. Balance sheet: strong liquidity (2.5x). Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.7B |
| Beta | 0.83 |
| 52W Range | $107.00 - $175.51 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.70 |
| Forward P/E | 17.8 |
| Current P/E | 18.8 |
| YoY Growth | 6.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 6.9% to -1.2% (-8.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.17% (CS: 42) | Neutral |
| RSI_14 | 56.9 | Neutral |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 1.009x | Above |
| vs SMA50 | 1.109x | Above |
| vs SMA200 | 1.072x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $142.35
- **Stop Loss:** $131.87 (7.4% risk)
- **Target:** $152.83 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 47
- **Position Value:** $6,690.45
- **Portfolio %:** 6.69%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-26 (Est: $1.69)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $2.03 | +41.6% |
| 2025Q2 | $1.50 | $2.10 | +40.0% |
| 2025Q1 | $1.28 | $1.72 | +34.4% |
| 2024Q4 | $1.48 | $2.11 | +42.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*